Sifalimumab
id:
sifalimumab-318-9184184
title:
Sifalimumab
text:
Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis. It targets interferon a. Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials.
brand slug:
wiki
category slug:
encyclopedia
description:
Human monoclonal antibody
original url:
https://en.wikipedia.org/wiki/Sifalimumab
date created:
date modified:
2023-12-20T19:24:10Z
main entity:
{"identifier":"Q7511830","url":"https://www.wikidata.org/entity/Q7511830"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/3/3e/Sifalimumab_4YPG.png","width":1353,"height":2048}
fields total:
13
integrity:
15